Local News
Eyewitness Sports
Call For Action
What's On WPRI
What's On Fox
2 Minute Test Drive
Experts Online
Online Store
Station Info

MARKETPLACE:  Auto | Jobs | Personals | Yellow Pages  September 19, 2004
Education | House & Home | Money | Pets | Recipes | Relationships | Travel | Weddings
What's Next | More Topics...
Two New Breast Cancer Therapies Show Promise
Email to a Friend Printer Friendly Version  

Researchers reported on the effectiveness of two new breast cancer drugs at the annual meeting of the American Society of Clinical Oncology in New Orleans.

The first, called lapatinib and taken orally, "inhibited tumor growth in nearly half of women who took it for eight weeks in a national Phase I clinical trial," according to a report prepared by the Duke University Comprehensive Cancer Center.

One of the main purposes of the trials, said Duke oncologist Dr. Kimberly Blackwell, was to find an alternative for women whose tumors didn't respond to two traditional breast cancer chemotherapies using Herceptin (trastuzumab).

The study showed that 46 percent of breast cancer patients who took lapatinib for eight weeks had their tumors shrink or remain stable. After four months, the study said, approximately 24 percent had stable disease or tumor shrinkage. The study was funded by GlaxoSmithKline, the maker of lapatinib.

Meanwhile, patients in the advanced stages of breast cancer live longer when they take a new drug, gemcitabine, in combination with a "traditional" chemotherapy drug paclitaxel, according to results presented at the same meeting. The multi-national study involved 529 patients and found that the combination therapy group had a significantly higher one-year survival rate.

"One year survival was 71 percent in the group that received the combination therapy, compared to 61 percent for the group treated with paclitaxel alone," said principal investigator and first author Dr. Kathy S. Albain, a director and oncologist at Loyola University's Cardinal Bernardin Cancer Center in Maywood, Ill. "These results are important because it was uncertain if earlier findings would translate into overall survival benefit," said Albain. "Now, we know they do," she said in a statement.

The study was funded by Eli Lilly and Co.


Copyright � 2004 ScoutNews, LLC. All rights reserved.

Health News | Health Encyclopedia | Quizzes and Tools | Women's Health | Men's Health | Children's Health | Seniors' Health | Diet, Fitness and Self Image | Sex and Relationships
Women's Health News  more» 
Exercise May Beat Breast Cancer in the Long Run
Radiation Not Always Needed for Breast Cancer
Age, Tumor Stage Affect Breast Cancer Death
Mammograms Point to Better Outcomes for Breast Cancer Patients
Antifungal Keeps Yeast Infections at Bay
Sugary Drinks Tied to Obesity, Type 2 Diabetes
MRI Spots Breast Tumors in High-Risk Women
Helping Breast Cancer Patients Make Tough Choices
Statins: The Next Miracle Drugs?
Radiology Advances Fight Breast Cancer
Health Encyclopedia: Women's Health
Dilatation And Curettage (D and C)
Breast Calcifications
Tubal Ligation
Vaginal Prolapse
Postpartum Depression
Prenatal Care
Prolapsed Uterus
Ovarian Cysts
Stuck in a rut?
Why not take a class? Learning something new is sure to inspire you.
Get in touch today!
Find friends, family, lost loves, military buddies, or anyone else you wish to reconnect with here.
In the Kitchen
This week, try our most popular dessert recipes.
Get the Facts
Free Alzheimer's tips & info by mail!
Soy and Your Health
Learn about the benefits of soy.
Send questions and comments about this website to the .
All content © Copyright 2004 WorldNow, WPRI, WNAC and Associated Press. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.